JP2008538506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538506A5 JP2008538506A5 JP2008507949A JP2008507949A JP2008538506A5 JP 2008538506 A5 JP2008538506 A5 JP 2008538506A5 JP 2008507949 A JP2008507949 A JP 2008507949A JP 2008507949 A JP2008507949 A JP 2008507949A JP 2008538506 A5 JP2008538506 A5 JP 2008538506A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- domain
- seq
- amino acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67434205P | 2005-04-22 | 2005-04-22 | |
| US60/674,342 | 2005-04-22 | ||
| US11/406,454 US7833979B2 (en) | 2005-04-22 | 2006-04-17 | Toxin peptide therapeutic agents |
| US11/406,454 | 2006-04-17 | ||
| PCT/US2006/015199 WO2006116156A2 (en) | 2005-04-22 | 2006-04-18 | Toxin peptides with extended blood halflife |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011276723A Division JP5220915B2 (ja) | 2005-04-22 | 2011-12-19 | 延長された血液半減期を有するトキシンペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008538506A JP2008538506A (ja) | 2008-10-30 |
| JP2008538506A5 true JP2008538506A5 (OSRAM) | 2010-02-12 |
| JP5087536B2 JP5087536B2 (ja) | 2012-12-05 |
Family
ID=37894298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507949A Expired - Fee Related JP5087536B2 (ja) | 2005-04-22 | 2006-04-18 | 延長された血液半減期を有するトキシンペプチド |
| JP2011276723A Expired - Fee Related JP5220915B2 (ja) | 2005-04-22 | 2011-12-19 | 延長された血液半減期を有するトキシンペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011276723A Expired - Fee Related JP5220915B2 (ja) | 2005-04-22 | 2011-12-19 | 延長された血液半減期を有するトキシンペプチド |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7833979B2 (OSRAM) |
| EP (1) | EP1896080A2 (OSRAM) |
| JP (2) | JP5087536B2 (OSRAM) |
| KR (2) | KR20100017942A (OSRAM) |
| AR (1) | AR053234A1 (OSRAM) |
| AU (1) | AU2006239928B8 (OSRAM) |
| BR (1) | BRPI0607750A2 (OSRAM) |
| CA (1) | CA2604999A1 (OSRAM) |
| CR (1) | CR9452A (OSRAM) |
| EA (1) | EA013470B1 (OSRAM) |
| IL (1) | IL186527A0 (OSRAM) |
| MX (1) | MX2007013031A (OSRAM) |
| NO (1) | NO20076013L (OSRAM) |
| NZ (1) | NZ562201A (OSRAM) |
| TW (1) | TW200716748A (OSRAM) |
| WO (1) | WO2006116156A2 (OSRAM) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB0414272D0 (en) * | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
| WO2008008873A2 (en) * | 2006-07-14 | 2008-01-17 | Georgia Tech Research Corporation | Clc channel ligand |
| WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
| AR063384A1 (es) | 2006-10-25 | 2009-01-28 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| CA2682605A1 (en) * | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| CA2686216C (en) | 2007-05-14 | 2016-04-12 | Universidad Nacional Autonoma De Mexico | Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) with high selectivity and decrease the in vivo dth-responses in rats |
| EP2158318A2 (en) * | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| EP2738257A1 (en) | 2007-05-22 | 2014-06-04 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| DK2215247T3 (en) * | 2007-11-13 | 2014-12-08 | Scripps Research Inst | Preparation of a fusion of cytotoxic antibody toxin into eukaryotic algae |
| EP2229473A4 (en) * | 2007-12-07 | 2011-02-02 | Steven A Goldstein | IDENTIFICATION OF TOXIN LIGANDS |
| CA2724384A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
| TWI388570B (zh) | 2008-07-23 | 2013-03-11 | 韓美科學有限公司 | 包含具有三個官能端的非肽醯聚合物的多肽複合物 |
| WO2010033222A2 (en) * | 2008-09-19 | 2010-03-25 | Netkar Therapeutics | Polymer conjugates of ziconotide peptides |
| EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
| EP2340045B1 (en) | 2008-09-19 | 2017-04-12 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
| US8252228B1 (en) * | 2008-10-13 | 2012-08-28 | Abbott Cardiovascular Systems Inc. | Methods for sterilizing carriers for treatment of a kidney |
| EP3385279B1 (en) * | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2010141329A1 (en) * | 2009-06-01 | 2010-12-09 | Medimmune, Llc | Molecules with extended half-lives and uses thereof |
| AU2010321832B2 (en) | 2009-11-20 | 2014-08-14 | Amgen Inc. | Anti-Orai1 antigen binding proteins and uses thereof |
| HRP20171291T1 (hr) * | 2010-02-04 | 2017-10-20 | Morphotek, Inc. | Polipeptidi i konjugati klorotoksina i njihove uporabe |
| CN103097403B (zh) * | 2010-05-11 | 2017-04-19 | 弗雷德哈钦森癌症研究中心 | 氯毒素变体、缀合物及其使用方法 |
| JP2013535692A (ja) | 2010-08-10 | 2013-09-12 | アムジエン・インコーポレーテツド | 標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ |
| EP2619226B1 (en) | 2010-09-22 | 2018-09-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| US9340590B2 (en) | 2011-03-16 | 2016-05-17 | Amgen Inc. | Potent and selective inhibitors of NaV1.3 and NaV1.7 |
| AU2012268441B2 (en) | 2011-06-06 | 2016-05-12 | Kineta One, Llc | ShK-based pharmaceutical compositions and methods of manufacturing and using the same |
| SG11201401193XA (en) * | 2011-10-03 | 2014-05-29 | Univ California | TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS |
| WO2013061106A1 (en) * | 2011-10-28 | 2013-05-02 | University Of Debrecen | Modified peptide toxins |
| WO2013065343A1 (ja) * | 2011-10-31 | 2013-05-10 | 株式会社 島津製作所 | 非ペプチドヒンジ部含有フレキシブル抗体様分子 |
| WO2013106489A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| KR20220051197A (ko) | 2012-05-17 | 2022-04-26 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
| US10414808B2 (en) | 2012-05-18 | 2019-09-17 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| US9102751B2 (en) | 2012-05-18 | 2015-08-11 | Janssen Biotech, Inc. | Huwentoxin-IV variants and methods of use |
| WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体－薬物コンジュゲート |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CA2913127A1 (en) | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
| JP6426107B2 (ja) | 2012-12-20 | 2018-11-21 | アムジエン・インコーポレーテツド | Ａｐｊ受容体アゴニストおよびその使用 |
| NZ709913A (en) | 2013-01-25 | 2019-05-31 | Janssen Biotech Inc | Kv1.3 antagonists and methods of use |
| EP2956165B1 (en) * | 2013-02-14 | 2019-09-11 | The Board of Trustees of the University of Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
| WO2014160037A2 (en) | 2013-03-14 | 2014-10-02 | The Regents Of The University Of California | Activatable membrane-interacting peptides and methods of use |
| US10640574B2 (en) * | 2013-07-18 | 2020-05-05 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementary determining regions |
| WO2015013330A2 (en) * | 2013-07-22 | 2015-01-29 | Kineta One, Llc | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| ES2841173T3 (es) | 2013-10-03 | 2021-07-07 | Janssen Biotech Inc | Variantes de Protoxina-II y métodos de uso |
| AU2013404615B2 (en) * | 2013-10-28 | 2018-05-17 | Baylor College Of Medicine | Novel scorpion toxin analogue and method for treating autoimmune diseases |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| HRP20190431T1 (hr) | 2014-01-31 | 2019-04-19 | Daiichi Sankyo Company, Limited | Anti-her2 antitijelo-lijek konjugat |
| CN111228511B (zh) | 2014-04-10 | 2024-06-18 | 第一三共株式会社 | 抗her3抗体-药物偶联物 |
| ES2754348T3 (es) | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
| GB201408135D0 (en) | 2014-05-08 | 2014-06-25 | Conogenetix Biosciences Gmbh | Kv1.3 potassium channel antagonists |
| EP3155002B1 (en) | 2014-06-10 | 2019-11-27 | Amgen Inc. | Apelin polypeptides |
| CN104177489B (zh) * | 2014-07-29 | 2017-03-22 | 暨南大学 | 基因重组TNF‑α衍生物RMP16及其制备方法与应用 |
| US20160045609A1 (en) * | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
| US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| JP6798998B2 (ja) * | 2014-11-07 | 2020-12-09 | キネタ・クロニック・ペイン・リミテッド・ライアビリティ・カンパニーＫｉｎｅｔａ Ｃｈｒｏｎｉｃ Ｐａｉｎ， ＬＬＣ | コノトキシンペプチドの修飾および使用 |
| WO2016112208A2 (en) * | 2015-01-09 | 2016-07-14 | Kineta One, Llp | Topical applications of kv1.3 channel blocking peptides to treat skin inflammation |
| MA41642A (fr) | 2015-03-03 | 2018-01-09 | Janssen Biotech Inc | Variants de protoxine ii et méthodes d'utilisation |
| TW201708249A (zh) | 2015-04-02 | 2017-03-01 | 健生生物科技公司 | 原毒素－ｉｉ變體及使用方法 |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| US20170209553A1 (en) | 2016-01-22 | 2017-07-27 | Transderm, Inc. | Delivery of botulinum with microneedle arrays |
| CA3021011A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| AU2017267793B2 (en) | 2016-05-20 | 2024-01-25 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
| KR102275008B1 (ko) | 2016-11-23 | 2021-07-13 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
| WO2018102777A1 (en) * | 2016-12-01 | 2018-06-07 | University Of South Florida | Peptibodies, compositions thereof, and methods of treating atrial fibrillation |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
| EP3572428A4 (en) | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| US10668113B2 (en) | 2017-03-31 | 2020-06-02 | Vivekananda Ramana | Formulation for targeting cancer in humans and canines using venom |
| US10668112B2 (en) | 2017-03-31 | 2020-06-02 | Vivekananda Ramana | Formulation for targeting cancer in humans and canines |
| US10668130B2 (en) | 2017-03-31 | 2020-06-02 | Vivekananda Ramana | Formulation for targeting cancer in humans and canines using chlorotoxin |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| TWI855528B (zh) | 2017-05-15 | 2024-09-11 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
| WO2019012015A1 (en) * | 2017-07-12 | 2019-01-17 | Iontas Limited | POTASIC CHANNEL INHIBITORS |
| KR20250084239A (ko) | 2017-08-31 | 2025-06-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
| JP7248578B2 (ja) | 2017-08-31 | 2023-03-29 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| WO2019074858A1 (en) * | 2017-10-09 | 2019-04-18 | Blaze Bioscience, Inc. | PEPTIDES BINDING TO IONIC CHANNELS AND METHODS OF USE |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| BR112020023330A2 (pt) | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| HRP20240756T1 (hr) | 2018-05-18 | 2024-09-13 | Daiichi Sankyo Co., Ltd. | Anti-muc1-eksatekan antitijelo-lijek konjugat |
| WO2019225296A1 (ja) * | 2018-05-24 | 2019-11-28 | 国立大学法人熊本大学 | 薬物送達用担体 |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| EP3831412A4 (en) | 2018-07-31 | 2022-04-27 | Daiichi Sankyo Company, Limited | TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| CN109106943B (zh) * | 2018-11-05 | 2021-04-20 | 中国科学院上海有机化学研究所 | 抗癫痫的毒素Martentoxin及其应用 |
| KR20220008866A (ko) | 2019-05-14 | 2022-01-21 | 하푼 테라퓨틱스, 인크. | EpCAM 결합 단백질 및 사용 방법 |
| CA3155089A1 (en) | 2019-09-20 | 2021-03-25 | Zealand Pharma A/S | Kv1.3 blockers |
| KR20220070246A (ko) | 2019-09-23 | 2022-05-30 | 디디에스 리서치 인크. | 침투 증진제를 갖는 지질 소포 조성물 |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| WO2022066767A2 (en) | 2020-09-23 | 2022-03-31 | Aldevron, Llc | Potent and selective inhibitors of nav1.7 |
| CN112353934B (zh) * | 2020-11-23 | 2023-05-19 | 中国人民解放军军事科学院军事医学研究院 | 一种芋螺毒素药物组合物及其冻干制剂 |
| BR112023019022A2 (pt) * | 2021-03-23 | 2023-10-17 | Zealand Pharma As | Bloqueadores de kv1.3 |
| EP4314013A4 (en) * | 2021-03-24 | 2025-09-17 | Glo Pharma Inc | MULTISOMAL LIPID VESICLES FOR THE DELIVERY OF COSMETIC AGENTS |
| EP4593867A2 (en) | 2022-09-30 | 2025-08-06 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| EP4604984A1 (en) | 2022-10-18 | 2025-08-27 | Zealand Pharma A/S | Inhibitors |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| JPH0669959B2 (ja) | 1985-09-26 | 1994-09-07 | 東燃株式会社 | コレラ毒素類を活性成分とする免疫抑制剤 |
| AU607172B2 (en) | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
| US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| JPH01502909A (ja) | 1987-02-24 | 1989-10-05 | ゾーマ・コーポレーション | 免疫毒素による人間の治療における免疫抑制 |
| US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| US5397702A (en) | 1989-03-06 | 1995-03-14 | The Regents Of The University Of California | Assay for and treatment of autoimmune diseases |
| US4994436A (en) * | 1989-03-10 | 1991-02-19 | American Air Liquide | Process for safely destroying organic binders in ceramic components during the firing process |
| US4906159A (en) | 1989-03-22 | 1990-03-06 | Caterpillar Industrial Inc. | Freely positionable load carrying attachment for an automatic guided vehicle |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| IL98932A0 (en) | 1990-07-27 | 1992-07-15 | Univ California | Assay,kits and methods based on nk+channel expression |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
| GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| JPH0640945A (ja) * | 1992-07-23 | 1994-02-15 | Kureha Chem Ind Co Ltd | Ｆｃフラグメント結合抗腫瘍剤 |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| US5494895A (en) | 1993-07-22 | 1996-02-27 | Merck & Co., Inc. | Scorpion peptide margatoxin with immunosuppressant activity |
| US5460820B1 (en) | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
| US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| CA2184002A1 (en) | 1994-02-23 | 1995-08-31 | Jeffrey M. Blaney | Method and compositions for increasing the serum half-life of pharmacologically active agents |
| FR2717688B1 (fr) | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| WO1996019198A1 (en) | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol drug formulations |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| US5763478A (en) | 1996-10-16 | 1998-06-09 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
| WO1998023639A2 (en) | 1996-11-27 | 1998-06-04 | University Of Florida | ShK TOXIN COMPOSITIONS AND METHODS OF USE |
| CA2247328C (en) | 1996-12-26 | 2007-01-30 | Suntory Limited | Neuropeptides originating in scorpion |
| US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| SG129211A1 (en) | 1997-11-06 | 2007-02-26 | Univ Singapore | Therapeutic molecules |
| US6551821B1 (en) | 1997-12-23 | 2003-04-22 | The Trustees Of Columbia University In The City Of New York | Brain cyclic nucleotide gated ion channel and uses thereof |
| US6703485B2 (en) | 1997-12-23 | 2004-03-09 | The Trustees Of Columbia University In The City Of New York | Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof |
| JP3515072B2 (ja) | 1998-01-23 | 2004-04-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 成長因子模倣物質、成長因子および阻害因子の同定に用いられる方法および組成物 |
| JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| US6166322A (en) * | 1999-04-16 | 2000-12-26 | Industrial Technology Research Institute | Encapulation process for mono-and polycrystalline silicon solar cell modules |
| US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| EP1623994A3 (en) | 1999-05-17 | 2008-07-16 | ConjuChem Biotechnologies Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6768002B1 (en) | 1999-06-22 | 2004-07-27 | E. I. Du Pont De Nemours And Company | Scorpion toxins |
| WO2000078958A2 (en) | 1999-06-22 | 2000-12-28 | E.I. Du Pont De Nemours And Company | Scorpion toxins from buthotus judaicus |
| US6096891A (en) | 1999-12-09 | 2000-08-01 | Air Products And Chemicals, Inc. | Process for the production of cyclic N,N'-dialkylureas |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| SE0000935D0 (sv) | 2000-03-21 | 2000-03-21 | Astrazeneca Ab | An inhalation device |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| AU5943201A (en) | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| EP1177806A1 (en) | 2000-08-04 | 2002-02-06 | The Technology Partnership Public Limited Company | Dry powder inhaler |
| PL362324A1 (en) * | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6861405B2 (en) | 2001-06-12 | 2005-03-01 | Yale University | Compositions and methods relating to glucose metabolism, weight control, and food intake |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| EP1463752A4 (en) | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| GB0219512D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
| US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| US20040152769A1 (en) | 2002-11-09 | 2004-08-05 | Ekwuribe Nnochiri Nkem | Modified carbamate-containing prodrugs and methods of synthesizing same |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| PT1641483E (pt) | 2003-06-12 | 2008-04-29 | Lilly Co Eli | Proteínas de fusão |
| WO2005047337A1 (en) | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| GB0414272D0 (en) | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
| US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| JP5118969B2 (ja) | 2004-10-07 | 2013-01-16 | ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア | Ｋｖ１．３カリウムチャネルの選択的阻害におけるＳｈＫトキシンの類似体ならびにその使用方法 |
| AR063384A1 (es) | 2006-10-25 | 2009-01-28 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
| EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
-
2006
- 2006-04-17 US US11/406,454 patent/US7833979B2/en active Active
- 2006-04-18 KR KR1020097027223A patent/KR20100017942A/ko not_active Withdrawn
- 2006-04-18 AU AU2006239928A patent/AU2006239928B8/en not_active Ceased
- 2006-04-18 EP EP06751051A patent/EP1896080A2/en not_active Withdrawn
- 2006-04-18 MX MX2007013031A patent/MX2007013031A/es active IP Right Grant
- 2006-04-18 BR BRPI0607750-1A patent/BRPI0607750A2/pt not_active IP Right Cessation
- 2006-04-18 JP JP2008507949A patent/JP5087536B2/ja not_active Expired - Fee Related
- 2006-04-18 WO PCT/US2006/015199 patent/WO2006116156A2/en not_active Ceased
- 2006-04-18 CA CA002604999A patent/CA2604999A1/en not_active Abandoned
- 2006-04-18 EA EA200702313A patent/EA013470B1/ru not_active IP Right Cessation
- 2006-04-18 KR KR1020077027146A patent/KR20080021606A/ko not_active Ceased
- 2006-04-18 NZ NZ562201A patent/NZ562201A/en not_active IP Right Cessation
- 2006-04-21 AR ARP060101572A patent/AR053234A1/es not_active Application Discontinuation
- 2006-04-24 TW TW095114588A patent/TW200716748A/zh unknown
-
2007
- 2007-10-09 IL IL186527A patent/IL186527A0/en unknown
- 2007-10-19 CR CR9452A patent/CR9452A/es not_active Application Discontinuation
- 2007-11-21 NO NO20076013A patent/NO20076013L/no not_active Application Discontinuation
-
2010
- 2010-11-02 US US12/938,294 patent/US8907071B2/en active Active
-
2011
- 2011-12-19 JP JP2011276723A patent/JP5220915B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4574007B2 (ja) | ポリオール−ｉｆｎ−ベータ複体 | |
| AU691225B2 (en) | Improved interferon polymer conjugates | |
| TW496870B (en) | Compositions methods for stimulating megakaryocyte growth and differentiation | |
| JP3177251B2 (ja) | Ｎ末端化学修飾タンパク質組成物および方法 | |
| JP2008524117A5 (OSRAM) | ||
| JP2010527607A5 (OSRAM) | ||
| CA2617064A1 (en) | Conjugates of a g-csf moiety and a polymer | |
| CN103228265A (zh) | 长效干扰素α缀合物的液体制剂 | |
| SK11882003A3 (sk) | Variant štandardného ľudského interferónu ß, nukleotidová sekvencia kódujúca tento variant, expresný vektor a hostiteľská bunka s jej obsahom, farmaceutický prostriedok s obsahom uvedeného variantu a jeho použitie | |
| WO2005084303A2 (en) | Interferon-beta polymer conjugates | |
| US20080206184A1 (en) | Chemically Modified Protein Compositions and Methods | |
| CN102038938A (zh) | 利用IFN-β治疗慢性炎性脱髓鞘性多神经病 | |
| CN100519581C (zh) | 干扰素-β复合物 | |
| MXPA00010223A (en) | Polyol-ifn-beta conjugates |